BiotechTube
Home/Pipeline/Prostate Cancer Detection Test

Prostate Cancer Detection Test

Prostate Cancer

Pre-clinicalActive

Key Facts

Indication
Prostate Cancer
Phase
Pre-clinical
Status
Active
Company
OTraces

About OTraces

OTraces is an early-stage biotech company building a versatile diagnostic platform focused on early disease detection through non-invasive sampling. Its core technology uses advanced computational methods to analyze biomarkers in the tumor microenvironment and other biological signals, claiming over 95% accuracy for various indications, with a highlighted 98.6% accuracy for a prostate cancer test. The company operates as a B2B co-development partner for diagnostic and therapeutic developers, aiming to integrate its analytical tools into existing workflows to enhance diagnostic precision and enable earlier intervention.

View full company profile

Therapeutic Areas

OncologyChronic Diseases

Other Prostate Cancer Drugs

DrugCompanyPhase
APVO442Aptevo TherapeuticsPreclinical
APVO452Aptevo TherapeuticsDiscovery
BIO 300Humanetics Corp.Not Specified
OpaganibRedHill BiopharmaPhase 2
MagSense™ PSMA Imaging AgentImagion BiosystemsPre‑clinical
Small-Molecule TherapeuticAIkido LabsPre-clinical
LeronlimabCytoDynPreclinical
CROES RegistryAngioDynamicsPost-Market Registry
Cannabics® PRST-33CNBX PharmaceuticalsDiscovery
HDP-103Heidelberg PharmaPreclinical
ENV105Kairos PharmaPhase 2
AI for Prostate CancerInvenio ImagingResearch